January 2014 in “edoc (University of Basel)” This research suggests that fluoxymesterone, an anabolic steroid, may inhibit a key enzyme, potentially contributing to cardiovascular issues by affecting cortisol's activation of mineralocorticoid receptors.
7 citations
,
April 2019 in “The Journal of Steroid Biochemistry and Molecular Biology” This study found that 11α-hydroxyprogesterone is a potent inhibitor of 11βHSD2 in vitro and may serve as a precursor to unique C11α-hydroxy steroids in prostate cancer tissue.
69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
54 citations
,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” This review discusses the potential of targeting glucocorticoid action as a treatment strategy for obesity and type-2 diabetes, highlighting promising animal study results but reports no new clinical findings.
196 citations
,
May 2001 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that SZ95 sebocytes and HaCaT keratinocytes exhibit distinct enzyme expressions and activities, implicating their different roles in androgen metabolism and homeostasis in vitro.